India Approves Donanemab for Alzheimer’s, but Experts Warn of High Costs and Access Barriers

Indian regulators have approved Eli Lilly’s Alzheimer’s drug donanemab, a breakthrough treatment for patients with mild cognitive impairment or mild Alzheimer’s disease, amidst concerns over high costs and access barriers.

Donanemab Approval Sparks Debate Over Cost and Access

The approval of donanemab comes as India faces a rapidly growing dementia burden, with an estimated 8.8 million people affected, with Alzheimer’s disease accounting for the majority of cases, according to estimates cited by Eli Lilly.

Donanemab works by clearing amyloid plaques in the brain, a biological hallmark of Alzheimer’s, and is among a new generation of therapies designed to alter the course of the disease itself.

Understanding the Clinical Benefit of Donanemab

The drug has shown promising results in clinical trials, slowing cognitive and functional decline by around 35% in patients with early symptomatic Alzheimer’s, according to the Phase III TRAILBLAZER-ALZ 2 clinical study.

However, experts stress that the figure is often misunderstood, and that patients generally continue to show decline, but slower than expected.

Market Impact and Details

• Donanemab is approved for patients with mild cognitive impairment or mild Alzheimer’s disease, making early diagnosis critical.
• The drug is expected to be priced at a premium, which may limit its accessibility to patients in India.
• Regulators had conducted thorough independent reviews of the data, and Eli Lilly remains confident in the therapy’s benefit-risk profile.

Key Takeaways

• Donanemab has been approved in India for patients with mild cognitive impairment or mild Alzheimer’s disease.
• The drug has shown promising results in clinical trials, slowing cognitive and functional decline by around 35%.
• However, experts stress that the clinical benefit of donanemab may be limited by high costs and access barriers.

FAQs

What is the cost of donanemab in India?

The exact cost of donanemab in India has not been disclosed, but experts expect it to be priced at a premium, which may limit its accessibility to patients.

What are the potential side effects of donanemab?

Donanemab has been associated with serious side effects, including infusion reactions and amyloid-related imaging abnormalities.

How does donanemab work?

Donanemab works by clearing amyloid plaques in the brain, a biological hallmark of Alzheimer’s, and is among a new generation of therapies designed to alter the course of the disease itself.

Conclusion

The approval of donanemab in India marks a significant milestone in the treatment of Alzheimer’s disease, but experts caution that its real-world impact may be limited by high costs and access barriers.

Eli Lilly remains confident in the therapy’s benefit-risk profile, but regulators and experts must carefully weigh the clinical benefit against the risks and costs associated with donanemab.

As India faces a rapidly growing dementia burden, it is essential to ensure that innovative treatments like donanemab are accessible to patients who need them most.